EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 3.0

Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports

Dao-Xing Deng, Ting Wang, Hui Sun, Jun Kong, Yuan-Yuan Zhang, Le-Qing Cao, Xiao-Dong Mo

Journal of Blood Medicine · 2026-01 · Volume 17 · 1-6

DOI: 10.2147/jbm.s565949 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Blood Medicine, 2026-01. Verfasst von Dao-Xing Deng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hemat…. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Febrile neutropenia develops in approximately three-quarters of recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Among them, carbapenem-resistant Enterobacterales (CRE) associated mortality reaches up to 70%. Thus, rapid identification of CRE-high-risk patients and prompt empiric CRE coverage are critical. Two allo-HSCT recipients whose febrile neutropenia persisted on empiric carbapenem were promptly escalated to imipenem/cilastatin/relebactam, alone or combined with aztreonam and tigecycline-before culture confirmation. Defervescence occurred within 24-48 h, inflammatory markers declined progressively, and clinical infection control was achieved. Successful neutrophil and platelet engraftment followed. Immediate empiric imipenem/cilastatin/relebactam for CRE-high-risk allo-HSCT recipients with febrile neutropenia rapidly controlled infections and permitted successful hematopoietic recovery. Prospective studies are warranted.

Schlagwörter

Stichwörter der Autor:innen

allogeneic hematopoietic stem cell transplantationcarbapenem-resistantempiric therapyfebrile neutropeniaimipenem/cilastatin/relebactam

Autor:innen und Institutionen

  • Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for He…

Zitieren

APA

Deng, D. X., Wang, T., Sun, H., Kong, J., Zhang, Y. Y., Cao, L. Q., & Mo, X. D. (2026). Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports. Journal of Blood Medicine, Volume 17, 1-6. https://doi.org/10.2147/jbm.s565949

Vancouver

Deng DX, Wang T, Sun H, Kong J, Zhang YY, Cao LQ, et al. Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports. Journal of Blood Medicine. 2026;Volume 17:1-6. doi:10.2147/jbm.s565949

BibTeX
@article{Deng2026,
  author = {Deng, Dao-Xing and Wang, Ting and Sun, Hui and Kong, Jun and Zhang, Yuan-Yuan and Cao, Le-Qing and Mo, Xiao-Dong},
  title = {Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports},
  journal = {Journal of Blood Medicine},
  year = {2026},
  volume = {Volume 17},
  pages = {1--6},
  doi = {10.2147/jbm.s565949}
}
Kostenlos starten →